

**2023**

**A**



**2023 3**

2023

A

..... **1**

..... **2**

..... **3**

..... 3

..... 13

..... 16

..... 17

..... **19**

..... **20**

..... 20

..... 20

..... 28

..... 28

..... 29

---

	Fujian Cosunter Pharmaceutical Co.,Ltd.
	15,926.70
	2001 6 28
	2015 4 22
	1-7
	355300
	0591-38265188
	0591-83052199
	www.cosunter.com
	linxiaohui@cosunter.com
	0591-38265188

---

---

**1**

1			
2			
3			
4			

5			
---	--	--	--

2

2015

	2022 1-9	2021	2020	2019
	12,014.95	6,898.95	4,747.18	5,321.34
	40.39%	18.62%	12.88%	12.83%

2022 9 30

215

119

96

189

87.91%

1

1

	2022.09.30	2021.12.31	2020.12.31	2019.12.31
	150,855.90	144,676.65	100,578.10	89,587.84
	49,298.26	39,692.29	42,379.36	32,015.08
	101,557.64	104,984.36	58,198.73	57,572.75
	98,539.79	104,335.51	57,659.75	56,557.56

2

	2022 1-9	2021	2020	2019
	29,746.65	37,044.22	36,848.94	41,486.63
	-8,730.26	-4,448.34	1,516.14	1,254.69
	-8,865.57	-4,569.12	1,534.96	1,214.95
	-8,163.72	-3,416.40	1,652.86	1,258.49
	-7,149.31	-3,488.66	1,482.45	1,074.19
	-7,583.31	-4,607.63	147.09	-353.42

3

	2022 1-9	2021	2020	2019
	-7,772.83	-1,776.48	1,559.75	3,398.81
	-15,701.99	-17,438.47	-3,500.97	-7,347.62
	14,354.24	44,557.86	6,168.16	4,730.25
	-9,120.58	25,342.92	4,226.93	781.44
	29,796.27	38,916.85	13,573.93	9,347.00

2

1

2010

		/		
	2022 1-9	-7.10%	-0.45	-0.45
	2021	-4.40%	-0.23	-0.23
	2020	2.60%	0.11	0.11
	2019	2.04%	0.08	0.08
	2022 1-9	-7.53%	-0.48	-0.48
	2021	-5.78%	-0.31	-0.31
	2020	0.26%	0.01	0.01
	2019	-0.67%	-0.03	-0.03

2

	2022.09.30 /2022 1-9	2021.12.31 /2021	2020.12.31 /2020	2019.12.31 /2019
	1.10	1.82	0.88	0.85
	0.92	1.55	0.70	0.70
	32.68%	27.44%	42.14%	35.74%
	7.76	7.57	7.64	7.34
	2.16	2.06	2.83	2.50
/	-0.49	-0.11	0.11	0.24
/	-0.57	1.60	0.30	0.06
/	6.19	6.57	4.12	

$=$  $=$  $=$  $/$  $=$  $/$

2

1

**3**

**4**

**5**

CRO

**3**

**1**

			1,258.49	1,652.86	-3,416.40
-8,163.72	2021	2022	1-9		
		5,321.34	4,747.18	6,898.95	12,014.95
					2020
2021	2022	1-9		1,246.16	2,667.73
5,602.83					

**2****3**

2021

2022 1-9  
7,772.83

1,776.48

**4**

**1**

GST-HG171

GST-HG121 GST-HG141

**2**

**3**

**4**

35

**5**

7,469.12

2,829.00

37.88%

17.76%

**6**

A

1.00

A

35

A

A

A

A

20

80%

20

20

/

20

1

$$P1=P0-D$$

2

$$P1=P0/ 1+N$$

3

$$P1= P0-D / 1+N$$

P0

D

N

P1

A

47,780,100

30%

A

6

A

94,800.00

1		82,080.00	74,800.00
2		20,000.00	20,000.00
		<b>102,080.00</b>	<b>94,800.00</b>

A

A

12

1

2

2022

2018

2021

2016

2022

2020 2021

2019

2022





2023 1 5

9

A

9

2023

2023

2023

A

A

2023 1 30

70,135,017

2022

A

A

2023

A

A

A

44.04%

2022

2022

A

<

>

18

1

1

2

1

[2023]000680

[2022]0010676

[2022]007793

1

2

3

4

5

6

**2**

[2023]000680

1

2

3

**3**

4

1

2

3

2023

80%

=

/

5

**8**

A

47,780,100

36.07%

**18**

**18**

**1**

2022 9 30

**2**

3

18

1

2

A

47,780,100

30%

30%

2021 6

2023 1

18

18

4

18

1

2

94,800.00

24,500.00

25.84%

30%

30%





(本页无正文，为《兴业证券股份有限公司关于福建广生堂药业股份有限公司2023年度向特定对象发行A股股票之上市保荐书》之签章页)

项目协办人:

王宇辉  
王宇辉

保荐代表人:

吴文杰  
吴文杰

周倩  
周倩

内核负责人:

石军  
石军

保荐业务负责人:

孔祥杰  
孔祥杰

保荐机构董事长兼法定代表人:

杨华辉  
杨华辉

